Abstract
Context: Epigenetic alterations in suppressor of cytokine signalling 3 (SOCS3) have been suggested as a potential biomarker in glioma.Objective: To investigate whether SOCS3 methylation could act as a biomarker for glioma grading and prognosis.Materials and methods: Glioma samples were evaluated by pyrosequencing and quantitative reverse transcription-polymerase chain reaction (qRT-PCR).Results: SOCS3 promoter methylation was more frequent in the WHO III and (anaplastic) oligoastrocytomas group. SOCS3 methylation status was significantly inversely correlated with mRNA expression level. Mutant IDH1 caused marked increase in SOCS3 methylation.Conclusion: SOCS3 methylation is a potential biomarker for grading and prognosis in human glioma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
